CLINICAL ROLE -
Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.
Insights, Future Considerations in FLT3 Inhibitors Following Allo-HCT in Patients With AML
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
Study Suggests Patients With Low-Risk CLL May Stop Specialized Follow-Up Visits
Pharmacy Focus: Oncology Edition - Experts See Promising Future for the Treatment of Acute Lymphoblastic Leukemia
Bispecific Antibodies Emerge in the Treatment of Multiple Myeloma
Study: Mutation Found to Make Follicular Lymphoma More Susceptible to Experimental Drug